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ENGLISH SUMMARY 
Diabetes is a frequent metabolic disorder defined by chronic hyperglycemia which is 
caused by a deficiency in the endocrine system. Detection of Type 2 diabetes and 
related complications are important in starting the proper treatment as early as 
possible because long-term complications take years to develop. Therefore, early 
treatment can delay or minimize these complications. One of the challenges is to find 
these patients before they develop serious complications. When patients are 
diagnosed with Type 2 diabetes, it is a challenge to identify, which patients will 
develop a specific complication. Diabetes affects most organs of the body - from the 
small blood vessels to the larger macro structures such as the heart. Patients may 
therefore get complications on both cognitive function, extremities, heart, kidney, 
eyes, etc. Targeting of treatment may be an important means to achieve the best 
possible individual treatment effects. Predictive models have the potential to help in 
diagnosing patients and targeting proper treatment. 
The PhD thesis summarizes the general use of predictive models in diabetes and focus 
on two main areas in the use of predictive models within Type 2 diabetes.  
The first part is concerning the diagnosis of latent diabetes in the common population 
using several types of screening approaches. The studies show that using predictive 
models help identify people with diabetes at an early stage. Our findings suggest that 
additional information could be used to increase the performance of such screening 
models. An extended feature search might also increase the performance compared 
to the more traditional developing of such models.  
The second part described in the thesis revolves around predicting which patients 
using insulin would be prone to large weight gains as a result of the treatment. The 
study show how the rate of weight change is highly associated with the weight change 
one and a half years later. Using our proposed model, the physician could screen the 
patient and identify a group with high incidence of excessive weight gain. The next 
step is to validate the models and investigate the impact of using these in a clinical 
setting.   
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DANSK RESUME 
Diabetes er en hyppig metabolisk lidelse defineret ved kronisk hyperglykæmi, der er 
forårsaget af en defekt i det endokrine system. Diagnostik af Type 2-diabetes og de 
relaterede komplikationer er vigtige at identificere for at starte den rette behandling 
så tidligt som muligt, idet langsigtede komplikationer tager år at udvikle. Det er 
derfor hensigtsmæssigt med tidlig behandling, da det kan forsinke eller minimere 
disse komplikationer væsentligt. En af udfordringerne er at opspore disse patienter, 
før de udvikler alvorlige komplikationer. Når patienter er diagnosticeret med Type 2-
diabetes, er det en udfordring at vide hvilke patienter, der vil udvikle hvilke 
komplikationer. Diabetes påvirker de fleste af kroppens organer, herunder 
ekstremiteter, hjerte, nyrer, øjne, kognitive funktion, med videre. Målretning af 
behandling kan være et vigtigt middel til at opnå de bedst mulige individuelle 
behandlingseffekter. Prædiktive modeller har potentiale til at styrke diagnosticering 
og målretning af behandlingen. 
Ph.d.-afhandlingen opsummerer forskning af prædiktive modeller i diabetes og 
fokuserer på to hovedområder i brugen af prognostiske modeller i Type 2-diabetes.  
Den første del omhandler opsporing af latent diabetes i befolkningen ved hjælp af 
flere typer screeningsmetoder. Studierne viser, at anvendelse af prædiktive modeller 
kan hjælpe med at identificere diabetikere i en tidlig fase. Resultaterne fra studierne 
tyder på, at yderligere oplysninger omkring patienten der ofte ikke anvendes i 
udviklingen af disse modeller, kan bruges til at øge effektiviteten af sådanne 
screeningsmodeller. En udvidet featuresøgning kan ligeledes øge effekten i forhold 
til de mere traditionelle metoder.  
Den anden del, beskrevet i denne afhandling, omhandler  prædiktion af patienter, der 
er tilbøjelige til store vægtforøgelse som følge af insulin-behandlingen. Studiet viser, 
hvordan hastigheden af vægtændring de første måneder er forbundet med 
vægtændringer halvandet år senere. Ved hjælp af vores foreslåede model, kan læger 
screene patienter og identificere en patientgruppe med risiko for høj vægtstigning. Et 
VII 
fremtidigt skridt vil være at validere modellerne og undersøge konsekvenserne af at 
bruge disse i klinisk praksis.
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 INTRODUCTION 
Diabetes is a frequent metabolic disorder defined by chronic hyperglycemia which is 
caused by a deficiency in the endocrine system1. The disease is a major cause of 
morbidity as well as premature mortality because of long-term complications such as 
cardiovascular disease, blindness, kidney failure, and amputations 2–4. With early 
diagnosis and subsequent lifelong good glycemic control and early treatment of 
complications – the patient with diabetes can have a good life quality and reduce the 
risk of  complications that compromise their well-being 1. 
Early diagnosis of Type 2 diabetes is thus very important as intensive diabetes control 
can reduce long-term complications 5–7. Emerging technologies such as predictive 
models have the potential to improve the diagnostics and treatment of patients 8. This 
thesis presents an overview of research in this area of predictive models within 
diabetes and the related complications. Furthermore, the thesis focus on two main 
areas in the use of predictive models within Type 2 diabetes. 
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 BACKGROUND  
The following section gives an understanding of the chronic disease diabetes, existing 
diagnostic methods, an introduction to the most common complications related to 
diabetes, and how these complications typically are treated. Furthermore, the section 
contains an introduction to predictive modeling and how these mathematical models 
can be used to diagnose and design specialized treatment plans. 
 
PREVALENCE 
In Denmark, approximately 320,000 people have diabetes 9. Furthermore, it is 
estimated that for every three persons diagnosed with Type 2 diabetes two persons 
have undiagnosed diabetes. The majority of people suffering from diabetes under age 
25 have Type 1 diabetes, while the vast majority of people suffering from diabetes 
over 25 years have Type 2 diabetes. 
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Figure 1 – undiagnosed percentage of people with diabetes  
 
The prevalence of Type 1 and Type 2 diabetes is increasing, but the number of people 
suffering from Type 2 diabetes is rising much faster due to increasing lifetime of the 
population and the obesity epidemic 10. The disease is associated with increased 
morbidity, increased mortality, and increased healthcare costs 10. Danish and foreign 
studies show that ~7% of the total health service budget is used to treat diabetes and 
complications affecting the kidneys, eyes, and cardiovascular system 11. 
In 2010, the prevalence of Type 2 diabetes in the United Kingdom, United States 
(U.S.), China and the United Arab Emirates ranged from 7% to 34% of the population 
12,13. Approximately 7 million people have undiagnosed diabetes in U.S. and when 
finally diagnosed, up to 30% show clinical manifestations of diabetic complications 
14. Worldwide, it is estimated that approximately 350 million people will be 
diagnosed with diabetes in 2025. The primary growth will occur in developing 
countries. 
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DIABETES 
Diabetes is defined by chronic hyperglycemia caused by one or more underlying 
causes. Some of these causes diabetes by a direct effect on beta cell function or by 
interfering with the effect of insulin in the peripheral tissues. In other cases, diabetes 
is part of a more generalized impact of several organs or organ systems. 
There are mainly two types of diabetes; Type 1 and Type 2 Diabetes. Diabetes occurs 
when the body cannot produce enough of the hormone insulin or uses insulin 
ineffectively (figure 2). Insulin works as a gatekeeper to let the cell’s membrane 
absorb glucose and uses it as an energy source. Because of an autoimmune process 
with very sudden onset, people with Type 1 diabetes lose their ability to produce 
adequate amounts of insulin and therefore need insulin therapy to survive. On the 
other hand, people with Type 2 diabetes can be overlooked and stay undiagnosed for 
years. People with Type 2 diabetes lose their ability to use insulin gradually during 
years. Those who are affected by Type 2 diabetes are often unaware of the long-term 
complications. 15,16 
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Figure 2 - a graphical illustration of the differences between a normal person, one with type 
1 diabetes and one with Type 2/gestational diabetes. 
 
TYPE 1 DIABETES  
Type 1 diabetes is characterized by a lack of insulin production due to problems 
related to the beta-cells in the islets of the Langerhans in the pancreas. In most cases, 
the underlying mechanism is an immune response targeting the islets 17. This 
response is caused by a combination of congenital genetic disposition and 
dispositions evoked by environmental factors. Type 1 diabetes occurs much more 
frequently in patients with other autoimmune diseases, such as celiac disease, 
Addison's disease, and Thyroid diseases. If there is a family history of any of these 
diseases, the risk for Type 1 diabetes is higher. The development is gradual, but the 
clinical onset is often acute. 
TYPE 2 DIABETES  
Type 2 diabetes is a complex heterogeneous condition in which the more recent 
genetic studies have revealed several subcategories 15. Type 2 diabetes is a result of 
an interaction between genetic predisposition and environmental factors - particularly 
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physical inactivity and obesity. Excess abdominal fat distribution and obesity (BMI> 
30 kg / m 2) have explained the majority of cases of Type 2 diabetes. In children and 
adolescents, with light hyperglycemia, there will often be diagnostic problems since 
they might have a slow progression in type 1 diabetes. This condition may later 
become insulin-dependent. Nevertheless, because of the increasing incidence of 
obesity the prevalence of children and adolescents with Type 2 diabetes is also 
growing, particularly among ethnic minorities 10. Type 2 diabetes typically occurs 
after the age of 40, but may also occur before. The average age at diagnosis for Type 
2 diabetes in Denmark is approximately 55 years. Approximately 5% of the Danish 
population suffers from diabetes, from which 80-90% of these are diagnosed with 
Type 2 diabetes and more than half of these are older than 65 years. 15 
 
DIAGNOSTIC OF DIABETES  
The symptoms of diabetes are: excessive thirst, large frequent urination, 
unintentional weight loss, recurrent infections. Diabetes can be diagnosed by 
evaluating glycated hemoglobin (HbA1c) taken from a blood sample. If the HbA1c 
reveals ≥48 mmol/mol (6.5%) the diagnosis can be suspected. However, the 
diagnosis must be confirmed by another sample. 
 
HbA1c is used for both diagnosis and monitoring of diabetes. HbA1c reflects a 
patient's mean plasma glucose over a longer period - approximately 3 months - since 
HbA1c glycation is a function of the concentration level of plasma glucose. 
Previously glucose tolerance test (OGTT) or fasting blood glucose (FPG) were used 
to diagnose diabetes 18. This is out phased because of a number of benefits from the 
use of HbA1c such as: the HbA1c assay is now standardized, analytical and biological 
variability is modest, fasting is unnecessary, and the association of cardiovascular 
disease is better for HbA1c than FPG. 19 
 
However, the HbA1c assay is not without limitations. For certain groups of patients, 
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the HbA1c cannot be used for diagnostic or at least uncertainties need to be 
incorporated. These are conditions, in which the erythrocyte’s life is affected. 
Furthermore, despite many advantages of using the HbA1c assay. The sensitivity of 
the HbA1c for finding latent diabetes, such as for screening purposes, may not be as 
sensitive compared to OGTT 19–23.  
SCREENING FOR DIABETES 
Type 2 diabetes have a long latent period. Screening for diabetes can be a means for 
early diagnosis of Type 2 diabetes. However, screening program is only used in few 
places. Before starting a screening process, the World Health Organization (WHO) 
has outlined 10 sensible criteria which have to be meet. These are as follows: 24.  
1. The condition sought should be an important health problem. 
2. There should be an accepted treatment for patients with the recognized disease. 
3. Facilities for diagnosis and treatment should be available. 
4. There should be a recognizable latent or early symptomatic stage. 
5. There should be a suitable test or examination. 
6. The test should be acceptable to the population. 
7. The natural history of the condition, including development from latent to declared 
disease, should be adequately understood. 
8. There should be an agreed policy on whom to treat as patients. 
9. The cost of case-finding (including diagnosis and treatment of patients diagnosed) 
should be economically balanced in relation to possible expenditure on medical care 
as a whole. 
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10. Case-finding should be a continuing process and not a “once and for all” project. 
Type 2 diabetes meets most of these criteria. Screening the entire population is not 
cost-effective, therefore priority in the screening process must rely on choosing 
people at high risk of Type 2 diabetes 25,26. Numerous studies of diabetes screening 
have been published during the last decade 12,27. Risk prediction or risk stratification 
models have a considerable potential to be applied in a screening context in order to 
identify high risk individuals who should subsequently undergo testing for diabetes 
12,27. 
TREATMENT OF DIABETES 
The treatment of diabetes is a multidisciplinary challenge which include physicians, 
nurses, general practitioners, social workers and nutritionists. In the management, 
key goals are often as follows28: 
 
1. Lowering the HbA1c. 
2. Avoiding episodes of hypoglycemia. 
3. Prevention, early diagnosis, and effective treatment of complications. 
4. Treatment of hypertension. 
5. Control of other risk factors related to cardiac diseases. 
6. Postprandial targeting. 
7. Relief of symptoms. 
8. Minimal injection frequency. 
Treatment of Type 2 diabetes mainly consists of a combination of lifestyle 
intervention and pharmacological treatment. There is evidence that early and 
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effective treatment programs are important for the prognosis of Type 2 diabetes and 
all patients, especially newly diagnosed, should be offered early pharmacologic 
treatment and interventions to improve lifestyle 29. Lifestyle intervention or non-
pharmacological treatment consists of disease-specific patient education; knowledge 
and skills about the disease; self-care; dietary treatment; consulting for physical 
activity; smoking cessation 29. 
Type 2 diabetic patients are at high risk of having or developing early cardiovascular 
disease and intensive treatment of all risk factors and smoking cessation is therefore 
important. Pharmacological treatment for hypertension often involve administration 
of angiotension-converting enzyme (ACE) inhibitor  29.  
The medical treatment used to regulate the blood glucose level often consists of 
metformin as a starting point, though many patients are eventually treated with 
insulin to reach the therapeutic targets. The strength of using metformin is that it is 
effective in lowering HbA1c and makes a minimal risk of hypoglycemia and weight 
gain. In addition to that Metformin is also easy to use and the related costs are low.29 
Insulin is used when treatment goals are not achieved with diet, exercise and oral 
medication. Especially younger patients with Type 2 diabetes will eventually require 
insulin, but also many elderly patients will eventually need additional insulin therapy. 
Insulin has two main effects. First, insulin stimulates the cells to absorb glucose from 
the bloodstream, in order to lower the blood glucose level. Inside the cells, the 
glucose may be used as "fuel" for the cell's many functions, or it may be stored as 
glycogen. The second major effect of insulin stimulates the hepatic production of 
glucose from the stored glycogen in the liver. When blood glucose is high and the 
amount of insulin in the blood increases, the insulin inhibitor the hepatic release of 
glucose. In contrast, when blood glucose is low and the amount of insulin drops, the 
liver's release of glucose increases. Insulin is however not without adverse effects. 
Insulin increases the incident of hypoglycemia and contribute to weight gain in some 
patients. The psychological barrier associated with insulin treatment and the 
accompanying weight gain can affect compliance and diabetic control. 30   
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DIABETES COMPLICATIONS 
Early mortality among diabetes patients continues to be much more frequent 
compared to the rest of the population. This is significantly influenced by the 
presence of late diabetic complications, such as diabetic nephropathy, retinopathy, 
neuropathy, and arteriosclerosis 31. Diabetes is a condition with substantial increased 
risk of late complications. This risk of getting late diabetic complications increases if 
the treatment is insufficient and the person with diabetes has a high blood glucose 
level, high blood pressure, and high cholesterol. Late complications are caused by 
damage to blood vessels and nerves. Insufficient diabetes control leads to narrowing 
and constrictions in the small blood vessels of the body These strictures leads to 
damage to the eyes, kidneys, nerves, feet, brain and heart. 29 
 
Table 1 – Late diabetic changes and complications 
Changes 
Neurological Vascular 
Sensomotoric 
neuropathy 
Autonomic 
neuropathy 
Macroangiopathy Microangiopathy 
Distal extremities Blood pressure 
Regulating vessels 
Bladder 
Intestine  Sexual 
function 
Lower extremity 
Neck  
Brain  
Coronary arteries 
Kidney 
glomeruli 
Retina Myocardium 
 
 
Diabetic retinopathy is considered as the most common complication among the late 
diabetic complications. The incidence of diabetic retinopathy is approximately 
10,000 cases of blindness every year in the U.S. 32. The risk of developing diabetic 
retinopathy or other microvascular complications depends on the duration and the 
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degree of hyperglycemia, and hypertension 32. Diabetic nephropathy is the leading 
cause of renal failure. The cause of diabetic nephropathy is not well understood, 
however it is assumed that the underlying mechanisms are the same as for other 
microvascular complications 33. The time a person is diagnosed with Type 2 diabetes, 
approximately 7 % already suffer from nephropathy. Diabetic neuropathy is a type 
of nerve damage that commonly occur when having diabetes. Hyperglycemia can 
injure the nerve fibers throughout the body. However, diabetic neuropathy most often 
damages the nerves in the distal body parts such as hands and feet. The prevalence of 
diabetic neuropathy rely on the duration of the having the disease and approximately 
50 percent of patients with diabetes will develop neuropathy 34.   
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STATISTICAL EVENT PREDICTION AND DETECTION 
Predictive modelling uses statistics to predict outcomes. Predictive modelling can be 
applied to any type of unknown event, regardless of when it occurred. In practice, 
this is often the art of separating different situations from each other as illustrated in 
figure 3. 35 
 
 
Figure 3 – illustrating the case of separating three classes using a decision boundary with 
two predictors/features.  
 
In a medical context, these methods have the potential to combine different types of 
information: from anthropometric, anamnestic, demographic, and biomarkers. The 
combined information of the patient might help in either a diagnostic result or a 
prognostic result 36. In clinical practice, a physician typically also use many of these 
information to diagnose a patient. The doctor asks the patient questions about 
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lifestyle, perhaps takes an ECG of the patient, and order a series of blood samples to 
test for several biomarkers. The combined amount of information would then make 
up the conclusion or create a working hypothesis about the patient´s health 37.  The 
interplay between different risk markers is complex and very hard to calculate by the 
human brain. For example, obesity is a well-known risk marker for diabetes, the same 
goes for smoking, and lack of exercise, but the combined risk is harder to estimate. 
Using predictive models makes it possible to combine the information in a systematic 
manner andproduce reliable results if used correctly 36. The result can help the 
physicians and other clinical staff making specialized treatment plans and estimating 
the prognosis of the specific patient.   
Modelling approach  
Developing a prediction model requires several components as seen in figure 4 38. In 
the following section, this process will be described in a structured manner.  
First, data needs to be acquired from the real world; hereafter noise and outliers must 
be removed  before the data can be modelled. Finding and selecting relevant features 
is one of the most important components in a successful prediction model 38.  This 
also leads back to the data acquisition.  
If the features or measurements do not contain relevant information about the event, 
the final model will not be successful. The features extraction can be explained as the 
transformation of information to something readable by the computer – e.g. features 
from an ECG could be pulse or premature beats which is a mathematical 
transformation from the original signal. It is not required that the feature is 
mathematically derived from the original information, e.g. age or gender are often 
used as a feature in a predictive model.  
The next component is training the chosen model - this is often done by searching for 
the best decision boundary separating the classes (figure 4).  The last component is 
to evaluate the model by testing it on new patient not used for training the model.  
This is extremely important to ensure that the model is general and not just fitted to 
our sample of training subjects 39.   
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Figure 4 – illustration of the components in developing a predictive model. 
 
  

Data acquisitions
Preprocessing
Feature extraction
Feature selection
Model selection/traning
Evaluation
Decision making problem from 
the real world
How to acquire data, how much 
data should be acquired ?
Noise removal, filtering, 
normalization, outlier remova
Extraction of relevant features 
from the available data, followed 
by selection of the minimum set 
of most relevant features. Both 
steps also contribute to 
dimensionality reduction
Choosing the type of classification 
model and training it with an 
appropriate learning algorithm
Estimating the true generalization 
performance of the classifier in 
the real world? Confidence in this 
estimation?
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 AIMS OF STUDIES 
Summary 
Diabetes is one of the leading causes of morbidities worldwide and half of the group 
of people suffering from diabetes do not know they suffer from it. Early diagnosis of 
diabetes is important because it can help to reduce and slow the progression of the 
complications. When received the diabetes diagnosis, it is crucial to target the right 
patient for the right treatment. Predictive models contribute to potentially help 
diagnosing people and targeting the right treatment on an individualized level.   
Study I  
The aim of study I was to review and present the literature on predictive models in 
screening for and the management of prevalent short- and long-term complications 
in diabetes. 
Study II 
Screening for diabetes thought to be a key factor for early diagnosis and treatment 
and hereby decrease the risk of late diabetic complication. We investigated the 
feasibility and performance of a model based on extended predictive features and 
compared it with two widely accepted models. The aim was to explore the possibility 
of developing a simple and accurate question based model for the use in screening 
for Type 2 diabetes. 
Study III 
Sensitivity of glycated hemoglobin (HbA1c) is not optimal in screening for patients 
with latent diabetes. The hypothesis of the study was that simple healthcare 
information would lead to improved accuracy. The aim was to improve methods for 
diabetes screening by using data from the National Health and Nutrition Examination 
Survey (NHANES) database (2005 to 2010). 
 
APP 29 
Study IV 
Undesired insulin associated weight gain has been a continued challenge in 
hypoglycemic therapy within Type 2 diabetes. However, if prediction of insulin 
associated weight gain was possible, screening on an individualized level could be 
conducted and targeted initiatives could be initiated to avoid or reduce weight gain. 
The aim of this study was to identify predictors of weight gain in insulin treated 
patients with Type 2 Diabetes included in the randomized controlled Copenhagen 
Insulin and Metformin Therapy (CIMT) trial. 
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 STUDY I 
 
Toward Big Data Analytics: Review of 
Predictive Models in Management of Diabetes 
and Its Complications 
Cichosz, Simon Lebech; Dencker Johansen, Mette; Hejlesen, Ole K 
Diabetes Science and technology, 2016 
 
INTRODUCTION 
With the arrival of electronic medical records, more information on physician-patient 
interactions is being captured and stored electronically. This era of ‘big health care 
data’ provides rich opportunities for pooling data and for exploring aspects of health 
care management and for predicting therapeutic outcomes that would otherwise defy 
analysis. Combining numerous information from several healthcare providers about 
the patient would increase the level of information significantly. 
Predictive models using various methods - from statistics to more complex pattern 
recognition - have the potential to fuse different kinds of patient information and 
output prognostic results in a clinical setting40.  This could be used for clinical 
decision support, disease surveillance and population health management to improve 
patient care 8.  
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Diabetes is one of the top priorities in medical science and health care management; 
and an abundance of data and information on these patients is therefore available. 
Diabetes is a very serious disease that can lead to a large number of very serious long-
term complications such as blindness, amputation and heart disease if not treated 
properly in time 2–4. Also, early stages of Type 2 diabetes are asymptomatic, so 
patients may go undiagnosed for years 41.  Treatment, especially with insulin, is not 
without adverse effects such as risk of hypoglycaemia and weight gain 1 42. Predictive 
models could potentially inform the management of these diabetes-related problems. 
Fortunately, the past few decades have seen rapidly growing awareness of the 
possibilities in the field of using available information for predicting diabetes 
outcomes. The amount of published papers has risen every year from five 
publications in 1990 to about 300 in 2015 43 as illustrated in Figure 5. 
The aim of the present paper is to narratively review the literature on predictive 
models in screening for and the management of prevalent short- and long-term 
complications in diabetes.  This could help facilitate the importance of this scientific 
area and focus future research on what have been done and what should be the next 
step. 
 
PREDICTIVE MODELS 
Predictive models often include multiple predictors (covariates) to estimate the 
probability or risk of a certain outcome or to classify that a certain outcome is 
present/absent (diagnostic prediction model) or will happen within a specific 
timeframe (prognostic prediction model) in an individual 44.  
Almost any statistical regression model can be used as a predictive model. Generally, 
there are two kinds of models: parametric and non-parametric ones. Parametric 
models make assumptions regarding the underlying data distribution, whereas non-
parametric models (and semi-parametric models) make fewer or no assumptions 
about the underlying distribution. The most common approach is to use a regression 
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model for prediction. This often also involves the use of classic statistical methods to 
construct the mode based on level of  statistical significance 27. Other, less common 
model approaches resort to complex mathematical analytics of the data.  These 
models often utilize a broad range of methods involving machine learning and pattern 
recognition, among others, 38,45, and they are often, but not always, limited to 
classification tree, neural network, k-nearest neighbor 38.  
The model is often trained on large number of individuals of the cohort and validated 
on a faction of the cohort data or on data from another study. Data could typically 
consist of single measurements or a time-series. In either case, some kind of signal 
processing or mathematical transformation is needed to extract relevant predictors. 
Whether simple parametric methods like linear regression or more sophisticated 
methods are deployed, c-statistics (ROC curve) and sensitivity/specificity are often 
used to evaluate the performance of the prediction model. Furthermore, each 
approach has pros and cons; however, an in-depth discussion of these aspects falls 
outside the scope of the present review.  
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Figure 5 - Number of publications index by PubMed with keywords “predictive AND model 
AND diabetes.” The 2015 count is extrapolated based on the number from May 27, 2015. 
 
PREDICTION MODELS FOR SCREENING 
In the United States alone, an estimated 7 million people have undiagnosed diabetes 
46; and when they are finally diagnosed, up to 30% show clinical manifestations of 
complications of diabetes. Early diagnosis of patients with Type 2 diabetes is thus 
very important, not least because intensive diabetes management can considerably 
reduce long-term complications 5–7.  
Screening entire populations is not cost-effective, and screening should therefore be 
restricted to groups that are at high risk for diabetes 25,26. Models predicting who are 
at risk for diabetes (prevalence) 47–56 or for developing diabetes in the near future 
(incidence)51,57–69 have therefore attracted much interest in the medical literature. 
Most models are variants of multivariable linear regression models; and most use 
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anthropometric, anamnestic and demographic information as predictors. The most 
common predictors included in these models are: body mass index (BMI), age and 
family history of diabetes and hypertension 27.  However, although the number of 
prediction models developed is large, only very few end up being used in clinical 
practice. The reasons for this are legion and mainly involve methodological 
shortcomings and a generally insufficient level of reporting in the studies in which 
the screening prediction models were developed. More specifically, the problematic 
issues typically encompass which predictors were included, how continuous 
variables were dichotomised, how missing values were dealt with, how adequate 
statistical measures were reported, or which procedures were used for validating the 
results 27. Furthermore, poor design and reporting could entail skepticism regarding 
the reliability and the clinical usefulness of a model. Debatably, regardless of how 
the model is developed, all that in the end matters is that the model works in a clinical 
setting. A typical problem in this respect is that when a model is externally validated 
in another sample, its accuracy often declines. This is, for example, the case with the 
model by Bang et al. 48 where the sensitivity/specificity dropped from 79/67% to 
72/62% in the external validation. Moreover, temporal validation also showed a drop 
(63/72%) in this model 54.    
PREDICTION MODELS FOR LONG-TERM COMPLICATIONS 
RETINOPATHY 
Diabetic retinopathy is a primary cause of blindness worldwide 32, and this serious 
complication of diabetes is already present at the time of clinical diagnosis of Type 2 
diabetes in some patients 70. In the Wisconsin Epidemiologic Study of Diabetic 
Retinopathy, 3.6% of patients with type 1 diabetes and 1.6% of patients with Type 2 
diabetes were blind 71. It is recommended that patients with Type 2 diabetes should 
have an initial comprehensive eye examination by an ophthalmologist or optometrist 
shortly after being diagnosed with diabetes 2. Subsequently, the patient should be 
included in a screening program 72. The optimal  interval for screening of this group 
of patients with diabetes is not certain; yet, in Denmark, patients are typically seen 
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once a year depending on the progression of the disease 73. There is a long latent 
period before visual loss, and progression of this disease is to large extent preventable 
and treatable. 
Several studies have focused on individualising the screening interval based on risk 
factors for retinopathy progression 74–76. Looker et al. 76 used hidden Markov models 
to calculate the probabilities of extending the interval for people with no visible 
retinopathy. The results showed that extending the interval involved only a small risk. 
Mehlsen et al. 77 constructed a multiple logistic regression model to adjust the 
screening interval in low-risk patients. The model on average prolonged the screening 
interval 2.9 times for type 1 diabetes patients and 1.2 times for Type 2 diabetes 
patients. Predictors included in the model were HbA1c, number of retinal 
haemorrhages and exudates, longer diabetes duration and blood pressure. Others have 
published a model usable for selecting a high-risk group among newly diagnosed 
patients with diabetes. This model was suitable for remote areas of the world and for 
developing countries with limited resources 78. Convincing evidence for using 
predictive models for treatment and prevention of retinopathy are yet to be seen. 
Retinopathy is a feared complication among patients and, in general, the costs of 
offering frequent screening to all patients are small.  
NEUROPATHY 
Diabetic peripheral neuropathy is frequent, and 50% of people with Type 2 diabetes 
have neuropathy and therefore feet at risk of developing diabetic foot ulcer 79. 
Diabetic neuropathy is known by the American Diabetes Association (ADA) as “the 
presence of symptoms and/or signs of peripheral nerve dysfunction in people with 
diabetes after the exclusion of other causes.” Food ulcer is one of the major 
complications in patients with diabetes, with a 15% lifetime risk of amputation. The 
risk of having a lower extremity amputation is up to 40 times higher among patients 
with diabetic than among the background population without diabetes 80. 
It has been reported that with early detection and proper multi-disciplinary treatment, 
the amputation rate can be reduced by up to 60-85% 79,81. 
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Many potential risk factors have been investigated over the years 82. However, much 
less attention had been devoted to developing and validating multivariate prediction 
models 83–86. In 2006, Boyko et al. 83 followed 1,285 diabetic veterans and published 
a prediction model based on seven commonly available clinical variables for 
development of foot ulcers. Later Monteiro-Soares & M. Dinis-Ribeiro 86 validated 
and updated Boyko et al.’s model in different settings. Monteiro-Soares & M. Dinis-
Ribeiro included information about patients’ footwear and increased the prediction 
capabilities from a receiver-operating characteristic (ROC) area under the curve 
(AUC) of 0.83 to 0.88. Yet, no fixed system has eventually been adopted, and the 
implementation of validation models in clinical practice remains limited 84. The 
potential of foot ulcer prediction models is large, but more studies are needed.  
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HEART DISEASE 
Diabetes is a well-known risk factor for coronary heart disease. Diabetes adds an 
about two-fold risk for a wide range of vascular diseases, independently of other 
conventional risk factors 87.  
Much research has been conducted in the field of developing predictive models or 
risk scores for at-risk individuals from the general population 88. One of the best  
models is the Framingham score 89, which has been widely accepted and includes 
diabetes as a predictor.  Several scores have been developed specifically to predict 
heart disease in patients with diabetes 89–101. The AUC of these models ranges from 
0.59 to 0.80. Typically, a Cox regression model or a logistic regression is used for 
prediction. The most frequently included predictors are sex, age, systolic blood 
pressure, cholesterol and smoking. Despite much effort within this field, most models 
still need to be proven valuable in daily care. According to the International Diabetes 
Federation, these models fall short of adequacy / are limited because they have not 
been proven useful in populations older than 65 years and because they have been 
applied in people in whom treatment to prevent heart disease had already been 
initiated72. Future research should focus on the impact of using  coronary heart 
disease prediction models in the daily care of diabetes patients 88. 
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PREDICTION MODELS FOR SHORT-TERM COMPLICATIONS 
HYPOGLYCAEMIA 
People with type 1 diabetes often experience episodes of hypoglycaemia because they 
need to reduce the level of blood sugar by using insulin 42. Also patients with Type 2 
diabetes may experience episodes of hypoglycaemia because of the increasing use of 
insulin in this group. The fear induced by hypoglycaemia is pronounced, and the 
clinical results of this condition are serious. The literature suggests that the incidence 
of hypoglycaemia requiring emergency assistance reaches 7.1% per year among 
patients with diabetes 102 and that as many as 6% of all deaths in patients with type 1 
diabetes are due to hypoglycaemia 103–105.   
The arrival of the Continuous Glucose Monitoring (CGM) system made it possible 
to frequently measure interstitial blood glucose, and many scientists have since 
investigated the opportunities offered by this new technology. However, using the 
CGM for prediction of hypoglycaemia involves accepting a certain proportion of 
false positive alarms 106–109. Hypoglycaemia affects the entire autonomic nervous 
system, including the heart, the brain and perspiration 110,111. This has led to 
development of prediction systems that include information from EEG, skin 
impedance measurements and electrocardiograms 107,112–114. Some have attempted to 
use the glucose content in perspiration to predict blood glucose levels 115,116. 
Moreover, the use of signal processing to make the CGM signal more accurate has 
also been investigated 117. Many methodologies have been explored in pursuit of 
finding the Holy Grail in reducing hypoglycaemia using a predictive alarm system. 
However, the differences in styles of reporting and uses of data essentially make these 
systems incomparable. 
One of the main challenges in predicting or detecting an early onset of a 
hypoglycaemic event is the lack of high-quality data for validating predictive models. 
It is known that CGM has a physiological lag time and, moreover, less precision in 
the lower glucose concentration range 118–120. Knowing the underlying blood glucose 
level is therefore necessary. One way to obtain such knowledge could be by 
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establishing access to a large, open database, as seen in other fields such as the MIT-
BIH Arrhythmia Database 121. This would make validation and comparison between 
the proposed models much more transparent and easy. 
INSULIN-ASSOCIATED WEIGHT GAIN 
In most patients with Type 2 diabetes, it will eventually be necessary to begin insulin 
treatment to achieve the therapeutic goal of HbA1c < 7 mmol/l (126 mg/dl) 1. The 
problem of weight gain induced by insulin has long been documented as an issue in 
diabetes treatment 30,122. In the Diabetes Control and Complications Trial (DCCT), 
the average weight gain of patients with type 1 diabetes undergoing intensive 
treatment was 5.1 kg compared with 2.4 kg in standard treatment arm, 123 and similar 
results are seen for Type 2 diabetes 124. This increase in weight can negatively affect 
the cardiovascular risk profile and increase morbidity and mortality when intensive 
treatment is postponed due to the patient’s fear of gaining weight 30.  Prediction of 
insulin-associated weight gain has attracted only little attention in the literature 125–
127 compared with other complication of diabetes. It is known that insulin dosage is a 
strong predictor of weight gain 128. Jansen et al. 125  followed 65 patients with diabetes 
during insulin treatment, and they proposed a regression model for “prediction” of 
weight gain. However, the model is not suitable for prospective usage as it requires 
data on 0-12 months of insulin dosage and any changes in insulin dosage. In addition, 
common performance measures are not reported in this study. Balkau et al. 126 
reported data on factors associated with insulin-associated weight gain in 2,179 
patients with Type 2 diabetes. They also proposed a model that could explain part of 
the weight gain, but their model was not operational for prospective usage in the 
clinic. Factors included in this model were HbA1c , BMI at baseline and information 
about insulin. In future, more studies within this new field are needed. 
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DISCUSSION 
Predictive models drawing on and analysing ‘big data’ are being used for the handling 
of many daily-task applications. Much sparser use has been made of predictive 
models in clinical practice, however 72,129. There are many reasons why this is so. 
First, a prediction model must provide valid and accurate estimates, and these 
estimates should be able to inform management and clinical decision-making and 
subsequently improve outcome and cost-effectiveness of care. Second, a prediction 
model must be accepted and understood by clinicians in order for the model to be 
adopted on a wider scale. These requirements often imply that the models become 
oversimplified, which could weaken their accuracy. Convincing documentation and 
evidence for all relevant aspects must be provided, which is not always possible in a 
pragmatic context. Prediction models are therefore often based simply on multiple 
logistics or similar linear regression. The advantage of this approach lies in the 
transparency of its functionality; however, this advantage comes at the cost of not 
taking into account that predictors are rarely independent. In future work, it would be 
interesting to further explore the potential of other methods taking predictor 
dependencies into account. Ultimately, prediction models have to prove useful in 
terms of impact, i.e. better patient outcome 44,130.  Such studies are time-consuming 
and expensive, and these impediments will have to be fought to reap the full benefit 
of the ‘big clinical data’ available. 
 
Much effort have been put into developing predictive models for use in the 
management of diabetes and its complications. However, in general, most of these 
models have not been implemented and the clinical impact has not been investigated. 
Although evidence from implementation is lacking, it is argued that predictive 
models do have the potential to transform the way healthcare providers use 
sophisticated technologies; and much insight may be gained and more informed 
decisions made by drawing on the large amount of electronically stored clinical data. 
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 STUDY II 
 
 
Improved Diabetes Screening Using an 
Extended Predictive Feature Search 
Cichosz, Simon Lebech; Dencker Johansen, Mette; Ejskjaer, Niels; 
Hansen, Troels Krarup; Hejlesen, Ole K 
Diabetes Technology and Therapeutics, 2014 
 
 
 
INTRODUCTION 
The prevalence of Type 2 diabetes is increasing, and the disease is associated with a 
major increase in morbidity, mortality, and healthcare costs 10. In 2010, the 
prevalence of Type 2 diabetes in the United Kingdom, United States, China and 
Arabic Emirates ranged from 7% to as high as 34% of the population 12,13. In the US, 
an estimated 7 million people have undiagnosed diabetes 46, and when finally 
diagnosed, up to 30% show clinical manifestations of diabetic complications 14. Early 
diagnosis of Type 2 diabetes is thus very important, as intensive diabetes control can 
significantly reduce long-term complications 5–7.  
 
In as much as screening entire populations is not cost-effective, priority in the 
screening process must rely on selecting those people at high risk for diabetes 25,26. 
Several studies of diabetes screening have been published during the last decade 12,27. 
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Risk prediction or risk stratification models have a substantial potential to be utilized 
in a screening context in order to identify high risk individuals who would 
subsequently undergo testing for diabetes.  These models often include a combination 
of predictors, such as anthropometrics, lifestyle, hereditary conditions and clinical 
measurements 27. Multivariable statistical methods, i.e. logistic regression, are used 
to combine these risk predictors into a model 27,131. Despite the large number of 
proposed models, not many are used in daily clinical practice. Optimal model 
performance is crucial for all tests. Most models are based on elimination of 
predictors with focus on statistical significance of the model which may not yield 
optimal performance 27. Cohort data obtained for a different scientific purpose is 
often used, and this can limit the models’ use in an entire population. Furthermore, 
attempts are often made to construct models that present risk scores that reflect the 
complexity of the data, but which also may be perceived as simple and applicable in 
clinical practice. This is commonly done by collapsing continuous variables into two 
or more categories, or preselecting predictors based on subjective judgment 132. From 
a performance point of view, this may lead to an oversimplification and deterioration 
of the effectiveness of the proposed models 133,134. 
In the present study, we investigated the feasibility and performance of a model based 
on extended predictive features and compared it with to two widely accepted models. 
RESEARCH DESIGN AND METHODS  
We used data from multiple years of the National Health and Nutrition Examination 
Survey (NHANES , 2005 to 2010) 135, where results from an oral glucose tolerance 
test (OGTT) and a fasting plasma glucose (FPG) test were available to identify 
persons with undiagnosed diabetes using a logistic classification model.  
The NHANES is a cross-sectional study conducted by the National Center for Health 
Statistics of the Centers for Disease Control and Prevention. To represent the U.S. 
population, NHANES used complex, multistage probability sampling of the civilian, 
non-institutionalized population. To produce reliable statistics, NHANES 
oversampled elderly persons and some racial and ethnic minorities. The participants 
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were limited to those aged 20 and above. Pregnant women and participants with 
diagnosed diabetes were excluded. Based on these data, we developed and tested a 
new model for diabetes screening and compared it with two accepted screening 
models.  
 
Selection of predictors to be included in this new model as well as validation of the 
model was done by v-fold cross-validation. We calculated all 16,383 possible 
combinations of predictors in order to find the optimal subset. We derived and tested 
the model on all combinations of 9 (of 10) partitions of training data and 1 (of 10) 
partitions of test data. The accepted statistical methods ensured valid testing of the 
model performance, reducing generalization bias 45,136. 
END POINT 
Our primary objective was detection of undiagnosed diabetes (prevalence) in the 
cohort of NHANES. OGTT results above or equal to 11.1 mmol/l or FPG above 7 
mmol/l were used as thresholds for the diagnosis of diabetes. ADA recommends that 
a test result diagnostic of diabetes should be repeated to rule out laboratory error, 
unless the diagnosis is clear on clinical grounds 137. Multiple test results were not 
available in our dataset, so one positive test was considered to be a diagnostic 
criterion.  
 
PREDICTIVE VARIABLES 
Multiple variables were selected to be investigated for their ability to distinguish 
between non-diabetics and undiagnosed diabetes.  We selected a number of well-
established risk factors, such as age, BMI and hereditary conditions 138–141, all 
available in the NHANES data set. In addition, we selected a number of more 
uncertain predictors, such as self-perceived oral health 142, which can be an early 
complication of diabetes 143 and socioeconomic status in the form of income and 
educational level, which have been associated with diabetes-related mortality 144.    
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Possible predictor candidates were  age, sex, family history of diabetes (yes/no) 
(questionnaire), history of hypertension (yes/no?) (questionnaire), BMI (body mass 
index), physically activity (yes/no) (questionnaire), waist circumference, educational 
level (questionnaire), income (questionnaire), race, self-perceived health 
(questionnaire), nicotine use (questionnaire), self-perceived dental condition 
(questionnaire) and blood pressure .  
The NHANES questionnaire concerning physical activity was changed from 2006 to 
2007 and forward. We considered the participants to be physically active if they 
answered “yes” to the question: “Over the past 30 days, did you do any vigorous 
activities for at least 10 minutes that caused heavy sweating, or large increases in 
breathing or heart rate?”  in the 2005-2006 cohort, or the question: “Do you carry out 
any vigorous-intensity sports, fitness, or recreational activities that cause large 
increases in breathing or heart rate, like jogging or basketball, for at least 10 minutes 
continuously?” in the 2007-2010 cohort. Participants’ family histories of diabetes 
were considered as binary without considering which family member had diabetes. 
Assessment of self-perceived oral health was formulated as “Rate the health of your 
teeth and gums” on a scale from 1(excellent) to 5 (poor). 
 
MISSING DATA 
We used multiple imputation to replace missing values. This imputation technique 
involves creating multiple copies of the data and replacing missing values with 
imputed values on the basis of a suitable random sample from their predicted 
distribution. Table 2 gives the distribution of missing values between variables 
included in the modeling. Multiple imputations allow patients with incomplete data 
to be included in analyses, thereby making full use of all available data and increasing 
precision and power without compromising validity 145. 
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COMPARISON WITH CONVENTIONAL MODELS 
Bang et al. (2009)146 used data from NHANES 1999 to 2004 to model and develop a 
“patient self-assessment score” for use in a wide variety of community settings and 
clinical encounters (including patient waiting rooms or on the Internet) via a simple 
pencil-and-paper method. In brief, the model was compared to several other scoring 
systems and validated on a cohort of approximately 21,000 participants, the primary 
end point being diagnosis of diabetes. The final model included variables of age, sex, 
obesity (BMI), history of hypertension, family history of diabetes and physical 
activity predictors, and was simplified for user-friendliness and presentation. Not 
many proposed models have been designed for and validated on an entire adult 
population (age > 20). This is one advantage of using the model formulated by Bang 
et al. (2009) as a foundation for comparison with our new model. In addition, we also 
used a model by Baan et al. (1999) 147, developed from a European Dutch population, 
for comparison. In brief, participants from the Rotter dam Study aged 55–75 years, 
not known to have diabetes completed a questionnaire on diabetes-related symptoms 
and risk factors and underwent a clinical examination.  The main findings from Baan 
et al. (1999) were that the additional information from the questionnaire sparsely 
improved the prediction capability compared to using routinely collected data only. 
We evaluated prediction models through sensitivity and specificity for pre-
determined cutoff points and receiver operating characteristics (ROCs) based on 
logistic regression models comparing the area under the curve (AUC) of the new 
model with that of the sparser models proposed by Bang et al. (2009)146 and Baan et 
al. (1999). We used student’s t-tests or z-tests for proportions in order to compare the 
difference between the groups with and without diabetes. 
 
RESULTS 
A total of 51 participants with diagnosed diabetes and 203 pregnant women were 
excluded. Thus, the study included a total of 5398 participants. The cohort 
characteristics are given in table 2. This cohort included 478 (8.8%, 478 of 5398) 
 
APP 47 
patients with undiagnosed Type 2 diabetes.  Participants with undiagnosed diabetes 
had a tendency to be older, had a lower level of physical activity level, higher waist 
circumference and BMI, were less educated, earned less income, had less use of 
nicotine and higher incidence of diabetes in their families than their counterparts 
without diabetes (P<0.05). 
The final model, selected on the basis of performance from all possible combinations 
of predictors, was composed of BMI, waist circumference, age, history of 
hypertension, family history of diabetes, physical activity, education level and race. 
Figure 6 presents the ROCs for the two models. The established models had AUCs 
of 0.74 and 0.71, respectively, compared with an AUC of 0.78 (P<0.05 for both 
comparisons) for the new model. Table 3 presents sensitivity, specificity, positive 
predictive value and negative predictive value at proposed cutoff points by Bang et 
al. (2009) compared to the new model and the model by Baan et al. with fixed 
specificity.  For the cutoff point of 4 (risk score), the established models yielded 
sensitivities of 82% and 57%, respectively, 95% CI [79.4; 83.7 %] and [55.1; 58.5 
%] and a specificity of 56% for both. The new extended model yielded a sensitivity 
of 85% with 95% CI [83.1; 87.6 %] when the specificity was maintained at the same 
level.  
Table 2 - Table presents the characteristics for the population studied, data presented as mean 
± standard deviation (sd) or proportion of the group. Missing data describe the percentage of 
participants lacking information about a particular predictor. NS = not Significant. 
 
Variable name 
Missing  
N(%) 
Non-diabetics  
N=4920 
Diabetics  
N=478 
P 
value 
BMI (kg/m²) 8.5% 28 ±6.4 31 ±6.6 P<.05 
Waist (cm)  1.8% 97 ±15 106 ±15 P<.05 
Gender (women %) 0 2465 (50%) 215(45%) P<.05 
Age (years)  4.8% 47 ±16 60 ±14 P<.05 
History of family diabetes? (yes %) 0 1824(37%) 201 (42%) P<.05 
Physically active? (yes %) 0 1331 (27%) 43 (9%) P<.05 
Told high blood pressure (yes %) 0 1429(29%)  25 
 (53%) 
P<.05 
Told high cholesterol (yes %)  30% 2070 (42%) 220 (46%) NS 
Education level (%) 0 - - - 
- Less than 9th grade - 490 (10%) 86 (18%) P<.05 
- 9-11th grade - 736 (15%) 82 (17%) NS 
- High school grad or 
equivalent 
- 1183(24%) 143 (30%) P<.05 
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- Some college or AA 
degree 
- 1380(28%)  105(22
%) 
P<.05 
- College graduate or 
above 
- 1134(23%) 62 (13%) P<.05 
Ratio of family income to poverty  7.2% 2.63 ±1.6 2.47 ±1.5 P<.05 
Race / Ethnicity (%) 0 - - - 
- Mexican American - 884 (18%) 96 (20%) NS 
- Other Hispanic - 441 (9%) 43 (9%) NS 
- Non-Hispanic White - 2465 (50%) 268 (56%) P<.05 
- Non-Hispanic Black - 887 (18%) 268 (12%) P<.05 
- Other Race (Including 
Multi-racial) 
- 243 (5%) 14 (3%) NS 
Self-perceived health (1-10)  3.7% 2.72 ±0.9 2.97 ±1.0 NS 
Nicotine use (yes %)  3.9% 1282 (26%) 105 (22%) P<.05 
Self-perceived dental cond. (1-10)  8.1% 3.23 ± 4 3.65 ± 7 NS 
 
For the cutoff point of 5 (risk score), the established model yielded sensitivity of 63% 
and 42%, respectively, 95% CI [61.7; 65.1 %] and [40.7; 42.9] and a specificity of 
72%. The new model yielded a sensitivity of 70% (95% CI [68.2; 71.9 %]) when the 
specificity was held at the same level. The new model thus yields better sensitivity at 
both cutoff points. The increased sensitivity from the new model corresponds to 
discovering 33 additional patients with diabetes compared to Bang et al. (2009) and 
an additional 129 patients compared to Baan et al. when the cutoff point of 5 (risk 
score) is used in the population sample. 
The total computation time for all  predictor combinations for the new model took  
approximately 8 hours on a standard laptop (Dell, Intel Core i5-2410 CPU @ 2.30 
GHz, 4 GB ram, 64-bit) using a self-written algorithm ( MATLAB® R2011b, 
Mathworks, Massachusetts, U.S.A). 
Tabel 3 - Sensitivity, specificity, positive predictive value (PPV) and negative predictive value 
(NPV) for different cutoff points. Sensitivities are shown with 95% confidence interval. 
Table 2 
NHANES 2005-
2010 (N=5398) 
 
 
Models 
 
Sen.% 
 
Spe. % 
  
PPV % 
 
NPV % 
Cut-off > 4 New model  85 [83.1;87.6] 56 14 98 
 Bang et al. ≥ 4 82 [79.4;83.7] 56  13 97 
 Rotterdam 57 [55.1; 58.5] 56 9 94 
Cut-off > 5 New model 70 [68.2;71.9] 72 18 97 
 Bang et al.≥ 5 63 [61.7;65.1] 72  16 96 
 Rotterdam  42 [40.7;42.9] 72 11 94 
 
 
APP 49 
 
Figure 6 - ROC curve for the detection of undiagnosed Type 2 diabetes. (A) = Logistic model 
including age, sex, family history of diabetes, history of hypertension, BMI, degree of 
physical activity, waist circumference, education level, income, race, health, nicotine use, 
dental condition, blood pressure. (B)= Bang et al. screening score (1-10) (based on age, sex, 
family history of diabetes, history of hypertension, BMI, physically activity). (C) = Baan et 
al. screening score,  using age, anti-hypertension medication, BMI and gender as predictors; 
uses the oral glucose tolerance test or fasting plasma glucose as the reference standard.   
 
DISCUSSION 
Numerous diabetes prediction models have been developed over the years 
12,27,131,132,146–149, and most studies use modeling approaches focusing on simplicity 
and statistical selection of predictors rather than performance. Most studies also use 
specific cohorts, which often exhibit small age ranges or racial/ ethnic origin groups, 
thus limiting their generalizability to an entire population. We explored whether an 
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extended investigation of predictor combinations could lead to better performance in 
a diabetes screening model for a population of people over age 20.  
Our results show that information about education level, racial/ethnic origin and 
waist circumference can significantly improve sensitivity and specificity of an 
established model when screening for diabetes by using a full investigation of 
possible predictor combinations. Using this kind of information can help reduce 
unwarranted screening for Type 2 diabetes, thus lowering costs26 of performing 
additional test such as HbA1c/OGTT for high-risk persons. Waist circumference 
and/or BMI have been used in most models 131,132,146–149, as has racial/ethnic origin, 
which is not surprising, as we know that racial differences are associated with the 
development of diabetes in some groups 53. To our knowledge, information about 
education level has not been used in screenings models, possibly because this kind of 
data is related to diabetes through lifestyle. Overall, however, it seems sensible to 
include this information.  Saydah et al. have shown that having less than a high school 
education was related to a 2-fold higher mortality from diabetes, after controlling for 
gender, age,  ethnicity, marital status, and BMI 144. 
 
The performance of the established model by Bang et al. (2009)146 in the present 
cohort was different from that originally reported when we examined it on our cohort. 
The cutoff point was ≥ 4 (risk score) and sensitivity and specificity were reported 
between 91-97 % and 38-51 %. Our validation yielded sensitivity and specificity 
levels of 82% and 56%, respectively.  The major difference between the studies was 
that we used a diagnostic criteria based upon FPG and OGTT, whereas the Bang 
model used only FPG, possibly because OGTT was only available in one of the two 
validation datasets. From the perspective of the ROC, the model by Baan et al. (1999) 
147 performed equal to that of Bang et al. (2009) for specificities above 80%. Below 
this threshold, however, the performance of Baan et al.’s model is inferior. Baan et 
al.’s model was originally developed and validated in a cohort aged 55 and above, 
which might explain the poor performance of the algorithm on a cohort which used 
an entire adult population.  
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These findings highlight the difficulties of comparing results across different 
population samples, even when identical underlying sample techniques are used. 
Models generally perform best on the data for which they have been developed, and 
they perform better on a training dataset than on a validation dataset 136. We used the 
accepted cross-validation approach, which is basically an average of the performance 
of multiple models 45,136. Our main concern when using this approach is the 
representativeness of the participants included in the study. NHANES uses complex, 
multistage probability sampling of the civilian, non-institutionalized population to 
create a realistic and representative sample of the U.S. population. Participants 
included in this study had an undiagnosed diabetes prevalence of 8.8%, which is 
significantly higher than the estimates from the International Diabetes Federation 
(IDF), which cite 2.6-3.4% of the U.S. population 150. Although our cohort is believed 
to be representative of the U.S. population, it should be emphasized that elderly 
persons and some racial and ethnic minorities, with higher prevalence of diabetes, 
have been oversampled in the NHANES. However, the comparison of our new model 
with the established models tested under similar conditions is valid, without a 
potential bias from the sampling. Several other studies have used (earlier) versions 
of the NHANES for the purpose of developing a diabetes screening model 53,146. 
Our end-point was undiagnosed diabetes by definition, although incidence prediction 
of diabetes and people with impaired glucose tolerance, also known as prediabetes, 
was beyond the scope of this study. In many respects, however, these issues are 
similar to those we have investigated. Hence, we believe our approach could add to 
these models as well 21. For a model to have generalizability over time and to other 
populations, the model needs to be validated precisely with respect to these factors 
136. Further validation of our screening approach with other samples and for other 
uses is therefore important.  
When developing models to predict undiagnosed diabetes, it is necessary to maintain 
a balance between including too many model variables and too few151. Automated 
variable selection methods have been used in most studies involving prediction of 
diabetes. Collins et al., in a systematic review of diabetes prediction, showed that 
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56% of the studies used automated variable selection to develop their model 27. These 
methods are suitable for pre-specified hypothesis testing, but in a 
predictive/classification approach, where performance is the goal, these techniques 
may not always yield optimal performance and in some cases may also create 
unstable models 152. 
The artificial simplicity presented in most models developed over the last decade is 
based on the belief that simplicity is the key in implementing a model successfully 
and in ensuring that it is accepted widely. Nevertheless, almost all models could 
easily be implemented in a standard webpage and made available for clinical use or 
to the public and still maintain the complexity without oversimplification. Our 
findings, based on a relatively large dataset of 5398 participants encompassing 
fourteen variables, showed that it is feasible to do a full investigation of the optimal 
subset of predictors to be included in the model. It should be noted, however, that in 
more complex datasets focusing on classification, elimination methods from machine 
learning can be used with success in a medical context 153. In brief, machine learning 
concerns the development and study of systems that can learn from data. 
 
We have shown how simple healthcare and economic data (such as ratio of family 
income to poverty) can help determine who is most at risk for undiagnosed diabetes.  
We have also shown that a calculation of all possible predictor combinations is 
feasible and can improve the performance of the predictive model. 
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A Novel Model Enhances HbA1c-based 
Diabetes Screening Using Simple 
Anthropometric, Anamnestic, and 
Demographic Information 
 
Cichosz, Simon Lebech; Dencker Johansen, Mette; Ejskjaer, Niels; 
Hansen, Troels Krarup; Hejlesen, Ole K 
Journal of Diabetes, 2014 
 
 
INTRODUCTION 
Diabetes and its complications are major causes of morbidity and mortality 
worldwide. An estimated 25.8 million U.S. citizens (8.3%) have diagnosed or 
undiagnosed diabetes46. The early stages of diabetes are asymptomatic, so people 
may go undiagnosed for years 41. Approximately 7 million people or one third of the 
entire population with diabetes in the U.S. have undiagnosed diabetes 46. Early 
diagnosis is important as early initiation of careful diabetes management can reduce 
long-term complications 5,6. Screening for diabetes can therefore be helpful in 
preventing major health problems in a large portion of the population. 
There is no clear consensus on the optimal screening test for detection of unknown 
diabetes. The most widely used tests include the oral glucose tolerance test (OGTT) 
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and the fasting plasma glucose (FPG) test 18. The OGTT test is considered the “golden 
standard” for detection of diabetes because it reflects some of the pathophysiological 
responses seen in diabetes.  However, both the OGTT and the FPG require the 
patients to be fasting for at least 8 hours, and OGTT is time-consuming, expensive, 
and inconvenient for the patient. Furthermore, repetition of the FPG  if initial results 
are positive is required to confirm the diagnosis, and the test is not as reliable as 
expected 154,155. The glycated hemoglobin (HbA1c) test has been suggested as an 
alternative screening test for Type 2 diabetes  and it has also been added as a first 
choice diagnostic criterion 137,156. Despite many advantages of using the HbA1c test, 
its sensitivity for finding latent diabetes, such as for screening purposes, compared 
with that of the OGTT may not be as sensitive19–23 - this is not unexpected as protein 
hyperglycation occurs secondary to abnormally high blood glucose, but there are 
limited data on how long the delay is. 157. Also intersubject variability in the form of 
biological factors may contributor to the level of glycation in different individuals 
158. We previously showed in newly diagnosed Type 2 diabetes patients that 
postprandial abnormalities were more pronounced than elevated HbA1c 159.  
Colagiuri and colleagues showed in a large data-pooling analysis that association of 
FPG, OGTT, HbA1c and retinopathy was similar between measures in relative 
numbers 160. In absolute quantities OGTT screening diagnoses more patients also 
containing most patients from HbA1c and FPG screening 21. Epidemiological studies 
have shown that a diabetes HbA1c threshold of 6.5% (48 mmol/mol) identifies only 
between 30 and 40% of previously undiagnosed patients with diabetes, whereas an 
OGTT identifies approximately 90% 21,157. The American Diabetes Association 
(ADA) similarly state this HbA1c sensitivity  problem in their 2013 position statement 
of diagnosis and classification of diabetes mellitus and recommend more research in 
the area 161.    
ADA also states that screening for diabetes should always be done in the pragmatic 
context of the patient’s life condition 137. In practice, the patient’s health information 
is taken into account, but to our knowledge, no screening method compares the use 
of this information within the context of a complete model for screening adults with 
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HbA1c. It could be speculated that this information would add value to the accuracy 
of HbA1c screening 162. 
 
This paper presents a novel screening algorithm for undiagnosed diabetes in 
multiethnic U.S. adults by using readily available health information combined with 
HbA1c measurement. Our aim was to improve methods for diabetes screening by 
using data from the National Health and Nutrition Examination Survey (NHANES) 
database (2005 to 2010). 
RESEARCH DESIGN AND METHODS  
STUDY DESIGN AND PARTICIPANTS 
We used a logistic regression classification model to combine information of HbA1c 
and health information for screening of undiagnosed diabetes and compared this 
approach with screening using HbA1c information alone. 
We used data from multiple years of NHANES (2005 to 2010) 135 for which  HbA1c 
and OGTT data were publicly available. 
We included participants aged above 20 for whom both HbA1c and OGTT data were 
available. Pregnant women and participants with known diabetes were excluded. For 
model fitting, we used multiple logistic regression classification with cases of 
undiagnosed diabetes as the end point. Undiagnosed diabetes was defined based on a 
two-hour blood glucose level above 11.1 mmol/L during an OGTT. For each 
participant, we retrieved data that were collected through physical examinations, 
interviews, and laboratory tests. 
MODEL DERIVATION AND DEVELOPMENT 
A model (HbA1c +) based on HbA1c results combined with additional available health 
information already know to be linked with the development of diabetes 138–141,163 was 
developed. The additional data were age, waist circumference, body mass index 
(BMI), gender, a family history of diabetes, and self-assessed level of physical 
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activity.  
We selected additional information data that were reasonably consistent from year to 
year and where only few data were missing (< 10%). The inclusion criteria for 
including predictors were mainly based on availability of data form year to year 
combined with scientific evidence of link between predictor and diabetes.  
The NHANES questionnaire concerning physical activity was changed from 2006 to 
2007 and forward. We consider the participants to have been physical active if they 
answered “yes” to the question “Over the past 30 days, did you do any vigorous 
activities for at least 10 minutes that caused heavy sweating, or large increases in 
breathing or heart rate” in the 2005-2006 cohort, or if they answered “yes” the 
question “Do you do any vigorous-intensity sports, fitness, or recreational activities 
that cause large increases in breathing or heart rate like running or basketball for at 
least 10 minutes continuously?” in the 2007-2010 cohort. Also the participant’s 
history of family diabetes was dichotomized as a “yes/no” question, i.e. it remained 
unspecified which other family member was having or had had diabetes.  
Backwards elimination was used to remove predictors that did not statistically 
improve the model. The process was iterative: predictors were removed until each 
predictor had a statistical significance level of P < 0.05. 
To avoid over-fitting and to remain able to utilize the entire cohort for validation, a 
cross-validation approach was used for model training and validation by randomly 
splitting the cohort into halves (two-fold cross-validation). The first half was used for 
training, while the second half was used for validation; this was then reversed and the 
results were averaged. To estimate confidence intervals of area under the curve 
(AUC) of the receiver-operating curve (ROC) cross-validation was used and the 
differences between AUCs were tested using a two sample student’s t-test. 
 
The results of the HbA1c+ model were compared with the results of the HbA1c alone.  
We calculated standard validation measures such as the sensitivity, specificity, 
positive predictive value (PPV), negative predictive value (NPV), and the AUC as a 
discrimination statistic. We compared the models’ sensitivities and specificities for 
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previously proposed HbA1c cutoff points such 6.1% (43 mmol/mol), 5.7% (39 
mmol/mol), and the diagnostic point of 6.5% (48 mmol/mol),  20,164. The 
corresponding specificity was matched in our model, and the sensitivity could then 
be compared between the two approaches. Modeling was done using MATLAB® 
R2011b (Mathworks, Massachusetts, U.S.A). 
MISSING DATA 
Because of proportions of missing data, we used multiple imputations to replace 
missing values. We thereby created multiple copies of data and replaced missing 
values with imputed values on the basis of a random sample from their predicted 
distribution. Multiple imputations allow patients with incomplete data to be included 
in analyses and hence full use of all the available data. This, in turn, increased the 
precision and the power of the study without compromising the validity of the model 
145. 
RESULTS 
A total of 51 participants with known diabetes and 203 pregnant women were 
excluded. Thus, the study included a total of 5381 participants.  The clinical 
characteristics of the cohort and the distribution of missing values between variables 
included in the modeling are shown in Table 4. This cohort included 7.5% 
undiagnosed Type 2 diabetes patients corresponding to 404 participants.   
Table 4 - Table presents the characteristics for the population studied, data are presented as 
mean ± standard deviation (sd) or proportion of the group. Missing data describe the 
percentage of participants for whom information about a particular predictor was missing. 
Variable name Missing  
(%) 
Patients without diabetes 
mean ± sd N=4977 
Patients with diabetes 
mean ± sd 
N=404 
HbA1c (%) 0 5.4 ± 0.6 6.4 ± 1.4 
BMI (kg/m²) 0.9 28.5 ± 6.4 30.6 ± 6.4 
Waist (cm) 1.7 97.8 ± 15.2 105 ± 15 
Gender (women%) 5 50 49 
Age (years) 4.8 47 ± 17 60 ± 14 
History of family 
diabetes? (yes%) 
0 37 42 
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Physically active? (yes%) 0 25 9 
Systolic blood pressure 
(mmHg) 
6 123 ± 18 134 ± 21 
Diastolic blood pressure 
(mmHg) 
6 69 ± 13 68 ± 17 
 
Participants with undiagnosed diabetes tended to be older, to do less physical activity, 
to have a larger waist circumference, a larger BMI, a higher systolic blood pressure, 
and a higher incidence of family diabetes than their counterparts without diabetes.  
Table 4 presents the final regression models derived from the development using two-
fold cross-validation. For the HbA1c+ model, HbA1c, age, waist circumference, and 
physical activity were significant predictors of undiagnosed diabetes. As seen in 
Table 4, HbA1c is the most important predictor of undiagnosed diabetes.   We assessed 
the diagnostic characteristics of different cutoff thresholds. Table 5 presents the 
performance of the models using these cutoff points.  Figure 7 represents the ROC 
for the two methods. As seen from the figure, the HbA1c have a saw-toothed 
appearance, which indicates that area of activity is much smaller for this method.  
Tabel 5 - Sensitivity (Sen), specificity (Spe), positive predictive value (PPV), negative 
predictive value (NPV) for different proposed cutoff points. 
Models Sen Spe PPV NPV 
Cutoff point 6.5% 
(48 mmol/mol) 
    
HbA1c 0.28 0.99 0.75 0.94 
HbA1c + 0.28 0.99 0.75 0.94 
Cutoff point 6.1%  
(43 mmol/mol) 
    
HbA1c  0.46 0.95 0.43 0.96 
HbA1c + 0.52 0.95 0.46 0.96 
Cutoff point 5.7% 
(39 mmol/mol) 
    
HbA1c 0.74 0.74 0.19 0.97 
HbA1c + 0.80 0.74 0.20 0.98 
 
 
For HbA1c, a cutoff point of ≥ 6.1 (43 mmol/mol) to have a high risk of undiagnosed 
diabetes; this cutoff point gave  a sensitivity of 46%, a specificity of 95%, a PPV of 
43%, and a NPV of 96%, with an ROC AUC 0.808 (95% confidence interval (CI 95), 
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0.786-0.829). For the HbA1c + matching the specificity yielded a sensitivity of 52%, 
a specificity of 95%, a PPV of 46%, and a NPV of 96% with an ROC AUC of 0.851 
(CI 95, 0.827-0.872). For HbA1c, a cutoff point of ≥ 6.5 (48 mmol/mol)  to have a 
high risk of undiagnosed diabetes; this cutoff gave a sensitivity of 28%, a specificity 
of 99%, a PPV of 75%, and a NPV of 94%; these results were identical for our model. 
There was a significant difference in the AUC between the HbA1c + model and the 
model using HbA1c without enhancement (P<0.05). The difference was estimated to 
0.042 (CI 95, 0.011-0.073). 
Figure 7 - ROC curve for the detection of unknown Type 2 diabetes (A) simple cutoff model 
with HbA1c (B) Logistic regression model including HbA1c, age, waist circumference, and a 
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question about physical activity - using the oral glucose tolerance test as the reference 
standard.   
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DISCUSSION 
The HbA1c threshold of 6.5% (48 mmol/mol), is recommended to be used to diagnose 
diabetes, but this threshold gives low accuracy in screening for diabetes. 
In the present study, we present a Type 2 diabetes screening model that draws on 
health care information and blood measurements of HbA1c. The logistic model was 
associated with an improved sensitivity when HbA1c was used in combination with 
additional healthcare information, especially for cutoff points with a specificity 
below <90%. Furthermore, the combined model produced a significantly larger ROC 
AUC than screening only with HbA1c . These results underline the importance of 
including covariates with known influence on diabetes diagnostics. 
 
Several studies and reviews have investigated the optimum cutoff point for HbA1c. 
Most report that the optimum cutoff point is 6.1% (43 mmol/mol). Wiener and 
Roberts 165 investigated FPG and HbA1c in patients undergoing OGTT. They found 
results comparable to ours: A HbA1c cutoff point of 6% gave a sensitivity of 51% and 
a specificity of 98%, while using the FPG with a 6 mmol/l cutoff gave a sensitivity 
of 90% and a specificity of 66% 165. In the Diabetes Control and Complications Trial 
and the UK Prospective Diabetes Study, which used comparable cutoff points of ≥ 
6.1% (43 mmol/mol),  the sensitivities ranged from 78 to 81% and the specificities 
from 79 to 84% in several studies166,167. In our study, this cutoff point offered a poor 
sensitivity of 46%, but a good specificity of 95%, and the most comparable sensitivity 
(74%) and specificity (74%) were reached with a lower cut-off value of 5.7% (39 
mmol/mol). This difference could possibly be explained by the composition of the 
population sample. The prevalence of undiagnosed diabetes in the participants in our 
study was 7.5%, which is significantly higher than ADA estimates, which correspond 
to nearly 1/3 of 7.5% in the U.S. population. A likely cause of the high prevalence of 
undiagnosed in the present study is NHANES oversampling of elderly people and 
racial and ethnic minorities who have a higher prevalence of diabetes than the general 
population. This problem is not unique for our study, but the problem hampers 
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accurate comparison across studies. Only few studies recruit from the general 
population 20,  and this fact introduces a potential selection bias . This underscores 
the need for validating the proposed screening model within the population in which 
it is intended to be used. 
The diagnostic HbA1c threshold for diabetes of 6.5% (48 mmol/mol) yielded a low 
sensitivity of only 28% for screening purposes, and adding additional information did 
not improve the sensitivity. This result is in good line with known knowledge 
regarding screening with HbA1c, where an HbA1c threshold of 6.5% identifies only 
30-40% of previously undiagnosed patients with diabetes 157.  
 
We found that, besides HbA1c , measures of obesity (waist circumference), age, and 
physical activity were important predictors of undiagnosed diabetes in our HbA1c+  
model. These findings are in line with previously described diabetes screening 
models 146,149. Compared with the results presented by Bang et al. 146, age and obesity 
were the best predictors  of risk. The magnitude of the odds ratios of these predictors 
was close to what we found.   
In a review on HbA1c as a screening tool, Bennett et al. 20 concluded that population-
specific cutoff points could be beneficial, as optimum cut-offs vary by ethnic group, 
age, gender, and the population’s prevalence of diabetes. To some extent, our model 
may be claimed to take account of this fact, but we did not include information about 
ethnicity/race. HbA1c have several limitations in screening use, the main limitations 
is the cost of the test which is much higher than FPG and OGTT, also the HbA1c is 
a poor predictor for impaired glucose tolerance (IGT). Furthermore Herman et al. 168 
concluded that HbA1c must be used carefully and in combination with traditional 
glucose criteria when screening and diagnosing diabetes. In a large dataset with 
representative samples, this potentially important variable could be included and this 
would possibly further improve screening.  
 
We used logistic regression as a linear method for modeling. This method is often 
used in population modeling because population growth follows a logistic curve and 
has a result that is easy to interpret.  But it is possible that methods such as support 
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vector machine (SVM) or neural network may also improve screening as these 
methods have been proven to produce good results in applications of machine 
learning 153. These methods also include an option for non-linear solutions. Further 
research should consider these possibilities when developing screening models 
within this area.  
It has been suggested that ROC curves should be used to find the optimal cutoff point 
in screening tests 169. The optimal cutoff point for maximizing sensitivity and 
specificity in ROC curves is defined as the 45 tangent in the upper left corner of the 
curve. However, this may not be the optimal cutoff point for a clinical test because 
practical considerations and the seriousness of the disease must also be taken into 
account when screening. We chose to compare sensitivity between models with a 
similar specificity derived from suggested cutoff points for HbA1c as screening tools. 
This makes it possible to compare different methods pairwise, but in practical use, 
the optimal sensitivity and specificity may, indeed, be very different. If high 
specificity is preferred, the additional gain from using our models is sparse. The AUC 
presented is based on calculations with trapezoidal approximation between discrete 
steps in the empirical ROC to estimate the area. This leads to an overestimation of 
the AUC for screening with only HbA1c. The (A) AUC in Figure 7 for HbA1c is 
significantly lower if more discrete steps are added equivalent to the number of steps 
in (B) HbA1c+. The HbA1c  AUC is then estimated to 0.787 (CI 95, 0.766-0.807) 
instead of 0.808. In future studies we also need to investigate ways to implement and 
to present the model as a tool in a clinical setting. 
 
In conclusion, we developed a simple screening model which could help improve 
screening for patients with undiagnosed Type 2 diabetes with HbA1c by adding 
additional healthcare information. 
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INTRODUCTION 
At diagnosis, the majority of individuals with Type 2 diabetes are obese, experience 
postprandial blood glucose excursions and have a sedentary lifestyle 141 159. 
Metformin is recommended as first-line diabetes drug to reduce blood glucose in 
order to  achieve a target of HbA1c < 53.0 mmol/mol (7.0%) but is not always 
sufficient 170. In many individuals, it will eventually be necessary to initiate insulin 
treatment to achieve the target glycemic goal.  
Along with the improvement of glycemic control, weight gain is a frequent challenge 
in insulin treatment 171. In the UKPDS individuals with type 2 diabetes assigned to 
the intensive group had an average weight gain approximately 4 kg more (3·1–4·9, 
p<0·0001) than the standard treatment arm 124. Insulin associated weight gain is 
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problematic for several reasons. For every gained kilogram, the risk of coronary heart 
disease increases along with adverse changes in the patient’s lipid profile and blood 
pressure 172–175. Additionally, when insulin treatment is postponed due to the patients 
fear of gaining weight, this can also negatively affect their cardiovascular risk profile 
and increase morbidity and mortality 30,176.  This psychological barrier associated 
with insulin treatment and the accompanying weight gain can affect compliance and 
diabetic control. Woman especially have been reported to omit or misuse insulin to 
manipulate with their weight 30. Weight gain with insulin therapy can be reduced, and 
being aware of the problem may help to avoid it 30,177. Lifestyle interventions such as 
exercise and diet programs have the potential to counter-act insulin-induced weight 
gain 178.  Moreover, the type of insulin and form of therapy, surgery, and weight loss 
agents could be options in preventing excessive weight gain 178.  
 
Few studies have tried to identify risk factors predict an excessive weight gain during 
insulin treatment among patients with Type 2 diabetes mellitus. Van Dieren et al. 179 
tried to determine the baseline characteristics and glucose-lowering therapies 
associated with weight change in patients from the ADVANCE trial. They found that 
weight gain was associated with younger age, Caucasian ethnicity, smoking and 
higher HbA1c.  
If prediction of excessive weight gain was possible on an individualized level, 
targeted initiatives could be carried out in order to avoid or reduce this undesired 
insulin associated weight gain. Previously, it has been shown how simple techniques 
from machine learning could be successfully used in similar medical challenges 
within diabetes 54,112,153,159. In this study, we investigate to what extent it is possible 
to predict individuals who will experience excessive weight gain during insulin 
treatment. 
RESEARCH DESIGN AND METHODS  
We used clinical available baseline data and 3-month control visit data from The 
Copenhagen Insulin and Metformin Therapy Trial (CIMT) 180. Our objective was to 
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investigate if this information could help to identify individuals with Type 2 diabetes 
who would experience excessive weight gain during insulin treatment.    
DATA COLLECTION 
The primary objective of the CIMT trial was to evaluate the effect of an 18-month 
treatment with metformin versus placebo in combination with one of three insulin 
analogue regimens. The primary results are described elsewhere 181,182. A total of 412 
participants with Type 2 diabetes over 30 years of age were randomly assigned to 
metformin/placebo in combination with one of the following insulin regimens: 
 Biphasic insulin aspart 30 before dinner with a possible increase to two or 
three daily injections. 
 Insulin aspart before the main meals (three times daily) and insulin detemir 
before bedtime. 
 Insulin detemir once daily before bedtime with a possible increase to two 
daily injections. 
 
 
 
Weight, medical history and blood samples were assessed at baseline. Every 3 
months during the 18-month trial, the participants were examined, and weight and 
blood samples collected. Table 1 shows the patient characteristics and data. 
All participants provided written informed consent before participation. The protocol 
was approved by the regional ethical committee (region of Copenhagen journal 
number H-D-2007-112) and the Danish Medicines Agency (journal number 2612-
3648) and was conducted in accordance with The Helsinki Declaration and guidelines 
for Good Clinical Practice. The overall amount of missing data used in this sub-study 
was low (<3%) and was handled using multiple imputation 183. 
The aim of this study was not to assess the arms; in this study, the patients from each 
arm were pooled together. 
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PREDICTION MODEL 
We developed a pattern classification method to predict individualized weight gain 
into one of two classes: small weight gain or weight loss (corresponding to 1st-3rd 
quartile) or excessive weight gain (corresponding to 4th quartile) during the 18-month 
trial.  
Logistic regression classification was chosen for basis of the model due to the 
possibility of including both nominal and ordinal data types. Moreover, logistic 
regression has a transparent decision model, which makes it appealing in a clinical 
setting as a decision support system. We used forward selection to include features 
in the model based on statistical significance. Moreover, we used 10-fold cross 
validation to ensure that the model was not over-fitted and that the results were 
transferrable to a similar cohort in the clinic. Predictor candidates used for inclusion 
are listed in table 1. 
 
We present and compare two instances of the classification model: (A) the 0-month 
model that uses baseline information, and (B) the 3-month model that uses baseline 
information as well as information about weight and insulin dose changes during the 
first three months of the trial.  
 
CLASSICAL STATISTICAL ANALYSIS 
Patient characteristics and results are presented as unadjusted mean ± (standard 
deviation) or median (25th; 75th percentile) as appropriate. For the purpose of testing 
for baseline differences between group characteristics, a two-way t-test was used for 
normal distributed data. A Chi-square test was used for proportions and in particular 
to test for difference in type of insulin regimen and insulin with and without 
metformin treatment between the groups. 
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RESULTS 
A total of 412 patients were included in this analysis.  
The median weight gain among the patients was 2.4 (95%: -5.6 ;12.4) kg during the 
18 months. 103 patients were excessive weight gainers, defines as the upper 4th 
quartile, the 75% upper threshold was a weight gain of 6.2 kg or more. The weight 
gain range in the 4th quartile was 6.2 to 22 kg with a median of 8.9 (95%: 6.3 ;15.2). 
The histogram for the weight changes are seen in figure 8 (top). In the bottom of 
figure 8 is seen the time dependent change in weight for the two groups. Noteworthy 
is that for the excessive gainers the weight gain is not saturating within the first 
months.  
 
The characteristics for the two groups are shown in table 6. The excessive weight 
gainers were at baseline on average younger with shorter duration of diabetes, with 
higher body weight. In addition, the group had a significant lower proportion of 
patients with prior insulin usage, but more patients with prior use of metformin. 
 
There was no statistical difference in type of insulin treatment between the groups. 
However, less patients received metformin + insulin during the trial in the excessive 
weigh gain group (P<0.001). Still, this information was not included in the final 
models because it did not yield any additional and independent information. 
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Table 6 - Baseline characteristics and information about insulin and weight changes the first 
3 months. Difference between Q1-3 and Q4 is test depending on data type and normality. 
Proportions is tested with chi square, normal distributed data are tested using two-sample t-
test and no normal distributed  are tested using Mann–Whitney U test. 
  Weight 
gain/loss Q1-
3 
Weight gain 
Q4 
p-value 
B
a
se
li
n
e 
d
a
ta
 
N  309 103  
Average 18 month weight gain (kg) (95 
prediction interval) 
0.9 (-6.1;5.3) 8.9 (6.3;15.2) P<0.05 
P ior insulin usage (%) 70 54 P<0.05 
Prior metformin usage (%) 79 96 P<0.05 
Age (years) 61.8±8.4 57.4±9.4 P<0.001 
Diabetes duration (years) 12 [9;18] 10 [7;13] P<0.05 
Gender, men (%) 69.7 67.7 NS 
Peripheral neuropathy symptoms (%) 42 22.6 P<0.05 
Retinopathy, score > 0 (%) 37 31 NS 
Autonomic neuropathy symptoms (%) 17.5 11.8 NS 
Systolic blood pressure (mmHg) 141±16 137.7±16 NS 
Diastolic blood pressure (mmHg) 82.1±10 84.3±9 NS 
Pulse (beats/min) 75.7±12.5 77.5±9.7 NS 
Microalbuminurea (%) 21.5 19.4 NS 
Macroalbuminurea (%) 4 8.6 NS 
Glomerular filtration (mL/min) 122.2±40 146.7±534 P<0.001 
Smoking (%) 15.3 18.3 NS 
Alcohol (units/wkr) 4.9±7.3 3±15.9 NS 
Weight (kg) 96.1±15.1 99.7±15.1 P<0.05 
BMI (kg/m2) 31.9±4.2 32.6±4.3 NS 
Waist hip ratio 1±0.1 1±0.1 NS 
HbA1c  (%) 8.5±1.1 8.7±1 NS 
Plasma glucose (mmol/l) 10.1±3.3 11.2±3.3 P<0.05 
Total daily insulin dose (IU/day) 48.7±35.3 45.6±29.8 NS 
C-peptide (pmol/L) 824.8±547.7 1018.1±474.7 P<0.05 
Total cholesterol (mmol/l) 4.2±0.9 3.9±0.8 P<0.05 
LDL cholesterol (mmol/l) 2.2±0.8 1.9±0.7 P<0.05 
HDL cholesterol (mmol/l) 1.2±0.3 1.1±0.3 P<0.05 
Very low density cholesterol (mmol/l) 0.8±0.4 0.9±0.4 P<0.05 
Triglycerides (mmol/l) 1.8±1.1 2±1 NS 
Insulin treatment    
 aspart+detemi (%) 34 34 NS 
 detemir (%) 35 24 NS 
 biphasic aspart (%) 31 42 NS 
Insulin+ metformin treatment (%) 56 34 P<0.001 
Daily insulin pr kg (IU/day/kg) 0.5±0.3 0.4±0.3 NS 
3
-
m
o
n
th
 3 month weight gain (kg) 0.1±2.7 3.0±3.5 P<0.05 
Daily insulin pr kg (IU/day/kg) @ 3 month 0.9±0.5 1.1±0.6 P<0.001 
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Baseline models performance 
The ROC’s for the baseline model are presented in figure 9. Significant predictors in 
the baseline  model for the risk of excessive weight gain are: younger age, shorter 
duration of diabetes years, higher glomerular filtration, smoking, alcohol 
consumption and prior insulin usage. The c-statistics for the model are, AUC 0.68, 
S.E. ± 0.061. 
3-month model performance  
The ROC’s for the 3-month model are presented in figure 9. Significant predictors 
included are lomerular filtration, 3 month weight gain, Daily insulin per kg. 
Furthermore, the gained weight the first three months is the most influencing 
predictor. Substantial improvements are seen from the baseline model (AUC 0.68, 
S.E. ± 0.061) to the 3-month model (AUC 0.80, S.E. ± 0.027) when including 
information of weight gain and insulin from the three month follow-up. Therefore 
focus will be on reporting model B in details. The 3-month-model B is presented in 
table 7. 
Table 7 - The table illustrate the implications of using the model to screen 1000 new similar 
patients with two scenarios; one using a low sensitivity and another using a high sensitivity. 
Screening scenario 
w. 1000 patients 
Sen Spe True  
positives 
False 
positives 
True 
negatives 
False 
negatives 
Prediction after 3 months       
Cutoff with high specificity 50 % 89 % 125 83 667 125 
Cutoff with high sensitivity 90 % 48 % 225 390 360 25 
 
 
For example, if we choose a cutoff with high specificity from the 3-month-model and 
used it  to predict patient with excessive weight gain. Given a sensitivity of 50% and 
a corresponding specificity of 89%. In a cohort of 1000 people with diabetes in 
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insulin treatment similar to our patients: 250 people would be excessive weight 
gainers and our purposed model would identify 125 of these people. In addition, the 
model would find 83 false positive. 
If we instead choose a cutoff with high sensitivity of 90% the corresponding 
specificity would be 48%. If the same 1000 people with diabetes were screened that 
would find 225 of the excessive weight gainers and 390 false positive. This screening 
scenario is listed in table 7. 
 
Figure 8 - The upper figure show the histogram for weight changes during the 18 months. 
The gray area show the 4th quartile (the participants with excessive weight gain). The lower 
figure show the development from each follow-up between the participants with excessive 
weight gain and the participants with small gain.   
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Figure 9 - Receiver operating characteristic for (A) the model using only baseline 
information and (B) using both baseline and 3-month follow-up information to predict 
excessive weight gain. 
 
DISCUSSION 
The present study highlights the clinical factors for prediction of weight gain in a 
cohort of individuals with Type 2 diabetes mellitus treated with insulin. Simple 
clinical variables may provide a clinically useful method for the prediction of 
excessive weight gainers in this population. Our cohort had a weight change of 2.4 
kg (95%: -5.6; 12.4) during the 18 months. This observed mean weight change is 
similar to what has been reported from UKPDS where the mean weight change was 
approximately 2.6 kg over the course of 18 months 124.  The delta weight gain the 
first three months was the strongest contributing factor in predicting the 18-month 
weight gain. This finding may not be surprising as this measure provides direct 
feedback from the patient’s weight response to the treatment. Although one-third of 
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the weight gain occurred in the first 3 month, it would not be preventable. It is 
noteworthy that the weight gains for the excessive weight gainers did not occur within 
the first months. 
Using the 3-month information is reasonable at preventing the overall weight gain 
during the follow-up because the predicting accuracy is much higher compared to 
using only baseline information for prediction. 
We found in our cohort that the group with the largest weight gain during the 18-
month follow up was associated with lower percentage of prior insulin usage. This 
finding is in line with established knowledge that the initial treatment of insulin is 
related to the largest weight gain during this treatment 30; in our study, the group with 
excessive weight gains were also younger, had shorter duration of diabetes and had 
fewer symptoms of peripheral neuropathy. These factors are connected and in line 
with the lower percentage of prior insulin usage. Balkau et al. 126 investigated factors 
associated with weight gain in people with Type 2 diabetes starting insulin treatment. 
They found that the main factors associated with weight gain were higher insulin 
dose, higher baseline HbA1c, and lower baseline BMI. In our study, we did not find 
an association with BMI or HbA1c. Nevertheless, initial weights were significantly 
different between the groups. Regarding HbA1c, our cohort had lower initial levels 
than the study group from Balkau et al., which could explain why this was not a 
significant predictor. Pontiroli et al. 128 also investigated factors associated with 
insulin related weight gain. They did not find baseline HbA1c as a predictor for weight 
gain. They also found that high insulin dose was associated with weight gain, which 
is also in line with our findings; daily insulin per kg (IU/day/kg) at 3 months was a 
highly significant (P<0.001) predictor for weight gain in our study. The amount of 
insulin prescribed was increased during the first visit (3 months from baseline) - 
possibly as a precaution when starting insulin treatment. This may be the reason why 
the baseline insulin prescribed was not a good predictor. The insulin given to each 
participant was continuously evaluated, but the three month doses were closely 
related to the average dose during the trial. This result explains why the baseline 
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insulin dosage was not a good predictor. 
 
Metformin usage during insulin treatment has been seen to reduce weight gain 184,185 
possibly because of lower insulin dosage needed to maintain low blood glucose 185. 
In our groups, the metformin+insulin treatment proportion was also lower in the 
excessive weight gain group. However, this information did not provide any 
independent predictive information; instead, information of insulin dosage was 
included in the model.   
Glomerular filtration rate was included in the model. This predictor did provide 
significant independent information but the impact of this predictor is very small (see 
table 2). It may be more practical if this predictor was removed from the model; 
however, it does provide independent information and could easily be set to an 
average estimated value when this information is not available in the clinic. 
 
One limitation of our proposed model is it would yield a significant proportion of 
false-positive predictions, depending on the chosen level of sensitivity/specificity. 
However, this might not be a major problem as interventions often consist of lifestyle 
modifications, which have few adverse effects and would benefit false-positive cases 
173. The number of false positives must be expected when trying to separate a group 
based on an arbitrary threshold such as the upper 4th quartile. In future work, we need 
to validate the model in other populations and also show the impact of the model used 
clinically and that the use of our proposed prediction model eventually leads to better 
patient outcome 44,130.  
In summary, we have demonstrated that the risk of excessive weight gain during 
insulin treatment may be predicted by using an algorithm that incorporates routine 
clinical variables and the delta weight change and insulin dosage during the first three 
months. Our findings extend the previous work performed in this field by developing 
an operable and simple model. 
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Given that a substantial proportion of the weight gain occurs in the first 3 months 
after initiating insulin therapy, a pragmatic approach would be to monitor on a 
monthly basis and in patients gaining more than 1 kg to start intervention in order to 
avoid further weight gain. In future work, the implications of implementing such 
model should be investigated.   
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 SUMMARY AND PERSPECTIVES 
The following section provides a summary of the thesis and a discussion of 
perspectives from the findings.  
Detection of diabetes and its complications is important in order to start a proper 
treatment as early as possible. It takes years to develop long-term complications. By 
treating people with diabetes, it is possible to delay or minimize the long-term 
complications. Nevertheless, it is challenging to identify relevant patients before they 
develop serious complications. When patients are diagnosed with Type 2 diabetes, it 
is difficult to know which patients will develop which types of complications. 
Diabetes affects most organs of the body - from the small blood vessels to the larger 
macro structures such as the heart. Patients may therefore obtain complications on 
both cognitive function, extremities, heart, kidney, eyes, etc. Specialized treatment 
may be an important means to achieve the best possible individual outcome. 
Predictive models have the potential to help diagnosing patients and targeting proper 
treatment.  
This PhD thesis summarizes the general use of predictive models in diabetes (study 
I) and focuses on two main areas in the use of predictive models within Type 2 
diabetes.  
The first part concerns the finding of latent diabetes in the common population using 
several types of screening approaches (study II-III). The studies show that using 
such predictive models can help identify people with diabetes at an early stage. Our 
findings suggest that additional information often excluded from these type of 
models, can be used to increase the performance of such screening models. An 
extended feature search might also increase the performance compared to the more 
traditional developing of such models.  
 
The second part described in this PhD thesis (study IV) revolves around predicting 
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which patients using insulin will be prone to large weight gains. The study shows 
how the rate of weight change is highly associated with the weight change 18-month 
year later. By using our proposed model, physicians might be able to screen the 
patients and identify a group with high incidence of excessive weight gain. 
There was an overlap in the use of the methods among the three studies (study II-
IV). Logistic regression was chosen for basis of the models due to the possibility of 
including both nominal and ordinal data types. Moreover, logistic regression has a 
transparent decision model, which makes it appealing in a clinical setting. This is a 
common approach when modelling in medical context (study I). However, it could 
be interesting to investigate how a different approach would influence the results. A 
non–linear type model might be better at modeling the relations between covariates 
and the dependent outcome.  
 
Performance of the algorithms (study II-IV) is an important aspect of their potential 
usefulness in a clinical setting. If the performance is low, either many false positive 
or few true positive has to be tolerated. In screening for diabetes (study II-III) this 
would lead to people needing subsequent testing. Subsequent testing is expensive and 
time consuming for both the people being tested and the medical staff.  If the model 
were used directly for diagnosis this could potentially lead to healthy people being 
wrongly diagnosed. More studies are needed to assess the cost-benefit of 
implementing these models. Both patient health benefits and socioeconomic factors 
must be taken into consideration. 
In people prone to excessive weight gain during insulin treatment, (study IV), poor 
screening performance would lead to either that few people with excessive weight 
gain would get an intensive treatment or that too many without the need for special 
treatment would get the intensive treatment. Criticism regarding the performance in 
study IV has been raised. One of the proposed cut off thresholds from the ROC yields 
a number of “need to treat” of three. Depending on the intervention chosen for the 
group, this is more of an economical challenge than a patient safety issue. One 
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proposed treatment would be some kind of lifestyle intervention with focus on eating 
and fitness habits. Hence, this would benefit most patient with type 2 diabetes prone 
to weight gain or not.       
To test the generalizability of the models, evaluation of additional datasets and 
datasets with different characteristics are needed. To avoid over-fitting a cross-
validation approach was used in study II-IV. Overall, this has shown high 
reproducibility in a different sample from the same cohort. However, the 
transportability of the models has not been validated. In study II-III, the models have 
been developed based on a sample from the American population (NHANES). The 
American population is known to be complex both in terms of ethnicity and socio-
economic conditions 186. It is be relevant to test the models in a north European 
country with homogenous demographics such as Denmark. In addition, temporal 
transportability could be relevant to investigate if the predictors in these studies are 
significantly influenced over time. Temporal validation could be tested by using an 
earlier version of NHANES. In study IV, we used a sample from a Danish 
multicenter trial. The patients were all recruited from the capital region. One concern 
about the generalizability in this study is that the protocol for starting and managing 
insulin treatment in Type 2 diabetes might be different in other countries. The models 
should therefore be validated in an external cohort to ensure the transportability. We 
know from study I that in general predictive models perform worse when validated 
on new data. In study II, we compared our approach to two models from Baan et al, 
and Bang et al. 48,49 – the performance of our proposed model was slightly increased. 
This seems promising, but we cannot make solid conclusions about improvements 
before we validate the methods.  
Implementation of the models from study II-VI in a clinical setting is also a 
noteworthy concern.  Study II shortly discusses what the challenges related to 
implementing the model in a clinical setting are. Now a day almost everybody has 
access to mobile devices such as a smart phones or tablets.  The natural thing would 
be to consider implementing these proposed models by using html5. Html5 has 
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several advantages; first, it is easy to build responsive web applications that are 
adaptable to the unit used for viewing the application. Second, html5 would also 
make it easy to port the web application to a native device application if the 
application should be used without internet access. Third, these applications are fast 
to update if required. Implementation could be accomplished by using an html5 
frontend, which handles the collection of patient data and presents the result in a clear 
manner. The logic of the model could be implemented in JavaScript directly or if 
computationally heavy logic were needed the JavaScript could utilize a web service 
where the logic was implemented in an alternative scripting language. 187 There is no 
need to simplify the models when the complexity of the models can be “hidden” in 
the backend implementation. The user can still interact with a simple, fast to use, and 
intuitive user interface.  
In a future perspective, what is missing is the implementation of such models (study 
II-IV) in clinical practice. Questions remain: will it affect the prognosis of these 
patients in a span of 10-20 year; will it increase life quality for these patients and will 
it increase or decrease the costs of the treatment. Screening large segments of the 
population is moreover a political decision. In study IV, idealistic, this information 
would help the physician and lead to proper treatment of the group prone to weight 
gains and as a result, the weight gains could be minimized. Realistic, specialized 
treatment for minimizing insulin associated weight gain is fare from effective and 
more research is needed to shed light upon new ways of avoiding these weight gains.  
 
CONCLUSION  
Predictive models have the potential to improve the way we make diagnosis and 
prognosis for patients. This PhD thesis shows how combining several information 
from patients in a structured way can lead to models, which can be used in a medical 
support system. The big question that remains to be answered is; are we ready to trust 
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new technology in the form of prediction models? Moreover, will it have these 
favorable effects as suggested by research?  
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